Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 12;25(23):7089–7097. doi: 10.1158/1078-0432.CCR-19-2004

Fig. 1. Response to EGFR inhibitors in preclinical patient-derived models.

Fig. 1.

PDXs established from class 2 (T599dup, K601E) or class 3 (D594N, G466V) mutant BRAF were treated with either vehicle or cetuximab. Each treatment group consisted of 5 mice. Error bars indicate standard deviation.